Psychedelics

Psychedelics developer secures $100 million to support the final phase of its application for regulatory approval to sell Ecstasy for PTSD

MAPS has launched a psychedelic-assisted therapy research program that has completed two Phase 3 studies and submitted an NDA to the FDA

US Patent and Trademark Office Publishes BetterLife’s Patent for BETR-001 and Other LSD Derivatives

This published U.S. patent is part of a developing international patent portfolio which cover new 2-bromo-LSD and other LSD derivatives.

Transcend Therapeutics, a mental health-focused biotechnology company, closes on $40 million

. While various psychedelics have demonstrated promise for the treatment of PTSD, Transcend focuses on a psychoactive compound that may...